Tag:
kidney cancer
Latest Headlines
Latest Headlines
UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
UPDATED: Aveo shares sink on weak PhIII face-off with Nexavar
Aiming at a regulatory filing for the experimental kidney cancer drug tivozanib later this year, Aveo Pharmaceuticals ( $AVEO ) unveiled a slate of late-stage data this morning designed to help build
Researchers decode some kidney cancer secrets
Knowing your enemy helps to defeat it. Researchers at the Van Andel Research Institute in Michigan kept that in mind with two separate studies that have helped unlock some secrets of certain kidney
'Smart bombs' deliver kidney cancer medication
Researchers at the Society of Nuclear Medicine in San Antonio, TX, are zapping kidney cancer cells with "smart bombs" made of a new form of radioimmunotherapy that zeroes in on antigens associated
'Synthetic lethality' strategy promising for kidney cancer
Stanford University researcher Amato Giacci has been working on a new approach to killing cancer cells called synthetic lethality. His lab has been seeking small molecules that target renal cells
NICE rejects kidney cancer meds, again
Another victory for Pfizer in the U.K. The National Institute for Health and Clinical Excellence once again decided against three kidney cancer drugs, leaving Pfizer's Sutent as the only cutting-edge
Avastin gets another FDA nod
Roche's Avastin got FDA approval for the most common type of kidney cancer, based on a study showing that patients on the drug in combination with intereron alpha lived nearly twice as long without
Novartis wins FDA approval for cancer blockbuster
The FDA has approved Novartis' Afinitor (everolimus) to treat the most common kind of kidney cancer. And analysts predict that the drug is on track to become a blockbuster, with new approvals for
NICE gives nod to just one kidney cancer med
The U.K.'s National Institute for Health and Clinical Excellence promised to reconsider four costly-but-cutting-edge kidney cancer drugs after its initial rejection fueled public outcry. Now, NICE
NICE to green-light costly kidney meds
A much-lamented ban on new kidney cancer drugs in the U.K. will soon be lifted, the Guardian reports. Of four meds that the National Institute for Health and Clinical Excellence called too expensive
